Genfit (GNFT) Q1 2026 TU earnings summary

Executive summary

• Cash and cash equivalents reached €136.1 million as of March 31, 2026, supporting operations beyond 2028 based on current assumptions.

• Revenue for Q1 2026 was €9.6 million, up from €2.8 million in Q1 2025, driven by royalties from IqirvoⓇ sales.

• Growth platforms include established PBC revenue, emerging MASH diagnostics, and innovation-driven programs in CCA, ACLF, and PSC.

• Positive commercial momentum for IqirvoⓇ, with accelerated US and European sales and early milestone achievement.

Financial highlights

• Q1 2026 revenue rose to €9.6 million from €2.8 million year-over-year, all from IqirvoⓇ royalties.

• IqirvoⓇ net sales for Q1 2026 were €78.8 million; full-year 2025 sales reached $208 million.

• €17 million milestone and €30 million royalty financing installment collected in early 2026.

Outlook and guidance

• Cash runway expected to fund operations and R&D beyond 2028, assuming continued milestone and royalty inflows.

• Anticipated commercial launch of NASHnextⓇ diagnostic by Labcorp in the coming weeks.

• Analyst event planned to discuss MASH diagnostics strategy and market potential.

• Pipeline update scheduled for Q3 2026, covering ACLF and UCD assets.